KOD Stock — Kodiak Sciences Inc.

Kodiak Sciences Inc. (KOD)

Updated October 16, 2026.

KOD is a Stock. Total return is 744.0% over the past 8 years, 546.8 points ahead of SPY at 197.2%.

Kodiak Sciences is a clinical-stage biopharmaceutical company developing therapies for retinal diseases, with its lead candidate tarcocimab tedromer in Phase 3 trials for diabetic retinopathy, wet age-related macular degeneration, and other retinal vascular conditions. The company does not currently distribute to shareholders. This security appeals to investors seeking exposure to early-stage biotech development with no current income component.

KOD performance versus SPY

Price and return data through 2026-10-16.

Total return is 744.0% over the past 8 years, 546.8 points ahead of SPY at 197.2%. Over the past year its total return — price change plus distributions reinvested — is 474.7%. Its deepest 1-year drawdown was 36.2%.

KOD key facts

Asset type

Stock

Asset class

Equity

Inception date

10/04/2018

Distribution frequency

None

Last close

$85.75 (as of 2026-10-16)

Market cap

$5,389,340,938

Average volume

1122131.0

Beta

2.035

Payout ratio

0.0%

EPS

$-4.19

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

KOD risks and drawbacks

The deepest 1-year drawdown on record here is 36.2%.

Who may consider KOD — and who may not

It is a weaker fit for investors who need monthly cash flow (KOD does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on KOD

• All tickers starting with K

Tagged: Healthcare.

Frequently asked questions